Aerie Pharma (AERI) Price Target Lowered to $27 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Canaccord Genuity Downgrades Aerie Pharma (AERI) to Hold
April 24, 2015 7:52 AM EDTCanaccord Genuity downgraded Aerie Pharma (NASDAQ: AERI) from Buy to Hold.
For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.
Shares of Aerie Pharma closed at $35.39 yesterday.
... MoreCantor Fitzgerald Downgrades Aerie Pharma (AERI) to Hold
April 24, 2015 6:38 AM EDTCantor Fitzgerald downgraded Aerie Pharma (NASDAQ: AERI) from Buy to Hold.
For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.
Shares of Aerie Pharma closed at $35.39 yesterday.
... MoreAerie Pharmaceuticals (AERI) RhopressaTM Phase 3 Trial Fails to Meet Primary Endpoint
April 23, 2015 4:06 PM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI) reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did... More
